临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
2014年
16期
1326-1329
,共4页
陈锐%仝晓敬%马跃%陶亚楠%王治海
陳銳%仝曉敬%馬躍%陶亞楠%王治海
진예%동효경%마약%도아남%왕치해
晚期恶性肿瘤%重组人P53腺病毒%化疗%肿瘤标志物
晚期噁性腫瘤%重組人P53腺病毒%化療%腫瘤標誌物
만기악성종류%중조인P53선병독%화료%종류표지물
Advanced malignancies%Recombinant adenovirus-P53%Chemotherapy%Tumor markers
目的探讨重组人P53腺病毒注射液联合化疗治疗晚期恶性肿瘤的近期临床疗效。方法收集晚期恶性肿瘤患者70例,采用重组人P53腺病毒注射液联合化疗方案治疗,评估患者的近期疗效及治疗前后肿瘤标志物癌胚抗原(CEA)、癌抗原199(CA199)和癌抗原153(CA153)水平。结果本组治疗有效率为55.7%,控制率为88.6%;治疗后鼻咽癌、胰腺癌、非小细胞肺癌和消化道癌的CEA水平均显著降低( P ﹤0.05);胰腺癌和消化道癌患者的CA199水平显著降低( P ﹤0.05),而鼻咽癌和非小细胞肺癌CA199水平无显著变化( P ﹥0.05);消化道癌CA153水平显著降低( P ﹤0.05);而鼻咽癌、胰腺癌和非小细胞肺癌患者CA153水平无显著变化( P ﹥0.05)。不良反应主要为化疗副性反应。结论重组人P53腺病毒注射液联合化疗治疗晚期恶性肿瘤具有显著近期疗效,能够改善患者的生存质量,毒副作用轻,值得推广应用。
目的探討重組人P53腺病毒註射液聯閤化療治療晚期噁性腫瘤的近期臨床療效。方法收集晚期噁性腫瘤患者70例,採用重組人P53腺病毒註射液聯閤化療方案治療,評估患者的近期療效及治療前後腫瘤標誌物癌胚抗原(CEA)、癌抗原199(CA199)和癌抗原153(CA153)水平。結果本組治療有效率為55.7%,控製率為88.6%;治療後鼻嚥癌、胰腺癌、非小細胞肺癌和消化道癌的CEA水平均顯著降低( P ﹤0.05);胰腺癌和消化道癌患者的CA199水平顯著降低( P ﹤0.05),而鼻嚥癌和非小細胞肺癌CA199水平無顯著變化( P ﹥0.05);消化道癌CA153水平顯著降低( P ﹤0.05);而鼻嚥癌、胰腺癌和非小細胞肺癌患者CA153水平無顯著變化( P ﹥0.05)。不良反應主要為化療副性反應。結論重組人P53腺病毒註射液聯閤化療治療晚期噁性腫瘤具有顯著近期療效,能夠改善患者的生存質量,毒副作用輕,值得推廣應用。
목적탐토중조인P53선병독주사액연합화료치료만기악성종류적근기림상료효。방법수집만기악성종류환자70례,채용중조인P53선병독주사액연합화료방안치료,평고환자적근기료효급치료전후종류표지물암배항원(CEA)、암항원199(CA199)화암항원153(CA153)수평。결과본조치료유효솔위55.7%,공제솔위88.6%;치료후비인암、이선암、비소세포폐암화소화도암적CEA수평균현저강저( P ﹤0.05);이선암화소화도암환자적CA199수평현저강저( P ﹤0.05),이비인암화비소세포폐암CA199수평무현저변화( P ﹥0.05);소화도암CA153수평현저강저( P ﹤0.05);이비인암、이선암화비소세포폐암환자CA153수평무현저변화( P ﹥0.05)。불량반응주요위화료부성반응。결론중조인P53선병독주사액연합화료치료만기악성종류구유현저근기료효,능구개선환자적생존질량,독부작용경,치득추엄응용。
Objective To investigate the effect of recombinant human P53 adenovirus injection(Gendicine)recent clinical curative effect of combined chemotherapy in the treatment of advanced malignant tumor. Methods 70 patients with advanced malignant tumor treated in our hospital used Gendicine combined chemotherapy in the treatment of patients. The treatment efficacy was evaluated. Results The effective rate of the treatment group was 55. 7%,control rate was 88. 6%. After the treatment of nasopharyngeal carcinoma,pancreatic cancer,NSCLC and gastrointestinal cancer,CEA tumor markers are significantly different from pre - therapy( P ﹤0. 05). In patients with pancreatic cancer and gastrointestinal cancer,tumor markers CA199 had significant difference( P ﹤0. 05). No obvious changes of CA199 in nasopharyngeal carcinoma and NSCLC group were found( P ﹥0. 05). The level of CA153 in gastrointestinal cancer,tumor marker showed significant different level( P ﹤ 0. 05). In gastrointestinal cancer pancreatic cancer and NSCLC,changes of CA153 is not significan(t P ﹥0. 05). The main adverse reactions is caused by chemotherapy. Conclusion Gendicine combined with chemotherapy in treatment of advanced malignant tumor has significant curative effect. This treatment method can improve the patient's quality of life. Side effects are not severely. It is worthy of popularization and application.